Harry Penner Jr. Buys Shares of Celldex Therapeutics
Harry Penner Jr. acquired 26,000 shares of Celldex Therapeutics, Inc. on June 25, 2026.
Key Points
- On June 25, 2026, Harry Penner Jr. bought 26,000 shares of Celldex Therapeutics, Inc., with the stock trading near $37.44 on Tuesday.
- Celldex Therapeutics has a market cap of about $2.77 billion and a forward P/E ratio indicating it is not currently profitable.
- Institutional investors like Wellington Management and Point72 Asset Management have adjusted their stakes in Celldex Therapeutics.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 25, 2026, Harry Penner Jr. purchased 26,000 shares of Celldex Therapeutics, Inc. (NasdaqCM: CLDX). The transaction was not part of a pre-arranged trading plan. Shares of Celldex traded near $37.44 on Tuesday.
Insider Buying and Selling at Celldex Therapeutics, Inc.
Several insiders, including Harry Penner Jr., bought shares of Celldex Therapeutics on June 25, 2026. Penner acquired 26,000 shares, while other insiders like Ronald Pepin, Sr. VP & CBO, and Samuel Bates Martin, SVP and CFO, also made purchases. These transactions were not under Rule 10b5-1 plans.
Celldex Therapeutics, Inc. Stock Down 4.3%
Shares of NasdaqCM:CLDX traded near $37.44 on Tuesday. Celldex Therapeutics has a market capitalization of approximately $2.77 billion. The company is not currently profitable, reflected by a forward P/E ratio that cannot be calculated. With a beta of 0.93, the stock has shown some volatility. The 52-week range is between $19.52 and $35.79, with moving averages of $32.10 over 50 days and $28.27 over 200 days. Celldex maintains a strong current ratio of 8.92 and a quick ratio of 8.78, with a low debt-to-equity ratio of 0.42.
$CLDX stock price
Daily closing prices, year to date. Not investment advice.
Other Institutional Activity in Celldex Therapeutics
Wellington Management Group increased its holdings in Celldex by 480,868 shares, ending with 8,560,476 shares valued at about $271.5 million. Point72 Asset Management made a significant move, adding 1,471,582 shares, bringing its total to 3,229,939 shares worth approximately $102.5 million, marking an 83.7% increase. Meanwhile, FMR LLC reduced its position by 1,158,421 shares, down to 3,749,048 shares valued at around $118.9 million, a 23.6% decrease.
Analysts Set New Price Targets
On June 15, 2026, HC Wainwright & Co. reiterated its buy rating on Celldex with a price target of $42. UBS maintained a buy rating with a target of $45 on June 10, 2026. Wells Fargo also maintained a buy rating with a target of $54 on May 13, 2026. The consensus among analysts is a strong buy, with a mean price target of $57.53 based on 15 opinions.
About Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company based in Hampton, New Jersey. It focuses on developing therapeutic antibodies for severe inflammatory, allergic, and autoimmune diseases. The company is advancing clinical programs like Barzolvolimab (CDX-0159) and CDX-622, targeting conditions such as chronic urticarias and inflammatory diseases. Led by CEO Anthony S. Marucci, Celldex employs around 198 people.
Bottom Line
Harry Penner Jr.'s purchase of 26,000 Celldex shares reflects ongoing interest in the company from insiders. Investors often watch insider transactions for potential insights into company prospects. With its focus on innovative treatments for challenging diseases, Celldex remains a company to watch in the biotechnology sector.
Get Celldex Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CLDX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.